Lung immune signatures define two groups of end-stage IPF patients.

Respir Res · 2023 · PMC10540496 · PMID 37770891

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

We therefore hypothesized that it is likely to be significant immune-related molecular heterogeneity in patients with IPF.

also in 279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.